| First-line nivolumab in stage IV or recurrent non–small-cell lung cancer DP Carbone, M Reck, L Paz-Ares, B Creelan, L Horn, M Steins, E Felip, ... New England Journal of Medicine 376 (25), 2415-2426, 2017 | 2481 | 2017 |
| Comprehensive and integrated genomic characterization of adult soft tissue sarcomas AJ Lazar, MD McLellan, MH Bailey, CA Miller, EL Appelbaum, MG Cordes, ... Cell 171 (4), 950-965, 2017 | 789 | 2017 |
| Combination epigenetic therapy has efficacy in patients with refractory advanced non–small cell lung cancer RA Juergens, J Wrangle, FP Vendetti, SC Murphy, M Zhao, B Coleman, ... Cancer discovery 1 (7), 598-607, 2011 | 730 | 2011 |
| Alterations of immune response of non-small cell lung cancer with azacytidine J Wrangle, W Wang, A Koch, H Easwaran, HP Mohammad, F Vendetti, ... Oncotarget 4 (11), 2067, 2013 | 403 | 2013 |
| ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial JM Wrangle, V Velcheti, MR Patel, E Garrett-Mayer, EG Hill, JG Ravenel, ... The Lancet Oncology 19 (5), 694-704, 2018 | 365 | 2018 |
| Early detection of lung cancer using DNA promoter hypermethylation in plasma and sputum A Hulbert, I Jusue-Torres, A Stark, C Chen, K Rodgers, B Lee, C Griffin, ... Clinical Cancer Research 23 (8), 1998-2005, 2017 | 258 | 2017 |
| Epigenetic therapy inhibits metastases by disrupting premetastatic niches Z Lu, J Zou, S Li, MJ Topper, Y Tao, H Zhang, X Jiao, W Xie, X Kong, ... Nature 579 (7798), 284-290, 2020 | 252 | 2020 |
| Neutrophil‐to‐lymphocyte ratio and overall survival in all sites of head and neck squamous cell carcinoma S Rachidi, K Wallace, JM Wrangle, TA Day, AJ Alberg, Z Li Head & neck 38 (S1), E1068-E1074, 2016 | 165 | 2016 |
| Molecularly targeted therapies in non–small-cell lung cancer annual update 2014 D Morgensztern, MJ Campo, SE Dahlberg, RC Doebele, E Garon, ... Journal of Thoracic Oncology 10 (1), S1-S63, 2015 | 154 | 2015 |
| Quantitative spatial profiling of PD-1/PD-L1 interaction and HLA-DR/IDO-1 predicts improved outcomes of anti–PD-1 therapies in metastatic melanoma DB Johnson, J Bordeaux, JY Kim, C Vaupel, DL Rimm, TH Ho, ... Clinical Cancer Research 24 (21), 5250-5260, 2018 | 138 | 2018 |
| IL-2 and beyond in cancer immunotherapy JM Wrangle, A Patterson, CB Johnson, DJ Neitzke, S Mehrotra, ... Journal of Interferon & Cytokine Research 38 (2), 45-68, 2018 | 114 | 2018 |
| Functional Identification of Cancer-Specific Methylation of CDO1, HOXA9, and TAC1 for the Diagnosis of Lung Cancer J Wrangle, EO Machida, L Danilova, A Hulbert, N Franco, W Zhang, ... Clinical Cancer Research 20 (7), 1856-1864, 2014 | 88 | 2014 |
| Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer. Cancer Discov. 2011; 1: 598–607. doi: 10.1158/2159-8290 RA Juergens, J Wrangle, FP Vendetti, SC Murphy, M Zhao, B Coleman, ... Biomarkers for EGFR-Antagonist Response, 2011 | 79 | 2011 |
| Prospective CT screening for lung cancer in a high-risk population: HIV-positive smokers A Hulbert, CM Hooker, JC Keruly, T Brown, K Horton, E Fishman, ... Journal of Thoracic Oncology 9 (6), 752-759, 2014 | 55 | 2014 |
| Extraction and processing of circulating DNA from large sample volumes using methylation on beads for the detection of rare epigenetic events B Keeley, A Stark, TR Pisanic II, R Kwak, Y Zhang, J Wrangle, S Baylin, ... Clinica chimica acta 425, 169-175, 2013 | 54 | 2013 |
| A phase 1–2 study of rovalpituzumab tesirine in combination with nivolumab plus or minus ipilimumab in patients with previously treated extensive-stage SCLC J Malhotra, P Nikolinakos, T Leal, J Lehman, D Morgensztern, JD Patel, ... Journal of Thoracic Oncology 16 (9), 1559-1569, 2021 | 52 | 2021 |
| Human immunodeficiency virus infection as a prognostic factor in surgical patients with non-small cell lung cancer CM Hooker, RA Meguid, A Hulbert, JT Taylor, J Shin, J Wrangle, ... The Annals of thoracic surgery 93 (2), 405-412, 2012 | 49 | 2012 |
| Chemoprevention of squamous cell carcinoma of the head and neck JM Wrangle, FR Khuri Current Opinion in Oncology 19 (3), 180-187, 2007 | 49 | 2007 |
| β-catenin and PI3Kδ inhibition expands precursor Th17 cells with heightened stemness and antitumor activity K Majchrzak, MH Nelson, JS Bowers, SR Bailey, MM Wyatt, JM Wrangle, ... JCI insight 2 (8), 2017 | 40 | 2017 |
| Safety and activity of CLN-081 (TAS6417) in NSCLC with EGFR Exon 20 insertion mutations (Ins20). Z Piotrowska, HA Yu, JCH Yang, M Koczywas, EF Smit, DSW Tan, ... Journal of Clinical Oncology 39 (15_suppl), 9077-9077, 2021 | 39 | 2021 |
malcolm brockJohns Hopkins School Of MedicineVerified email at jhmi.edu
